Poly(vinyl benzoate) nanoparticles for molecular delivery
The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC 50 >1000 μg/mL) and primary bovine primary aortic endothelial cells (IC 50 >500 μg/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 μg/mL). Poly(vinyl benzoate) nanoparticles are suitable carriers for molecular delivery of lipophilic small molecules such as drugs pharmaceutical and imaging agents.
1. A composition of nanoparticles comprising:
at least one biodegradable nanoparticle formed from poly(vinyl benzoate) and a block copolymer based on ethylene oxide and propylene oxide wherein the at least one nanoparticle is capable of entrapping lipophilic substrates;
a pharmaceutically acceptable carrier; and
a lipophilic molecules.
2. The composition of claim 1 , wherein the surfactant prevents opsonization.
3. The composition of claim 1 , wherein the at least one nanoparticle has a mean particle size of between about 50 nm and about 350 nm.
4. The composition of claim 1 , wherein the at least one nanoparticle has a mean particle size of between about 200 nm and about 250 nm.
5. The composition of claim 1 , wherein the size of the lipophilic molecule is up to about 5% by weight.
6. The composition of claim 1 , wherein the lipophilic molecule is an antibacterial agent.
7. The composition of claim 1 , wherein the lipophilic molecule is a drug.
8. A method of generating a small molecular drug carrier comprising:
nanoprecipitation of a polymer, further comprising
adding at least one surfactant to water, where the at least one surfactant is a block copolymer based on ethylene oxide and propylene oxide;
dissolving or diluting poly(vinyl benzoate) in acetone;
dissolving a predetermined quantity of lipid-soluble molecule in the acetone;
adding the poly(vinyl benzoate)-acetone solution to the water to form a mixture of a block copolymer based on ethylene oxide and propylene oxide and poly(vinyl benzoate);
stirring the mixture of a block copolymer based on ethylene oxide and propylene oxide and poly(vinyl benzoate); and
evaporating the acetone from the mixture of a block copolymer based on ethylene oxide and propylene oxide and poly(vinyl benzoate) to leave a suspension of polyvinyl benzoate nanoparticles.
9. The method of claim 8 , wherein the poly(vinyl benzoate) is added at about 0.5% (w/v) to the acetone.
10. The method of claim 8 , wherein the a block copolymer based on ethylene oxide and propylene oxide is added at about 0.5% w/v.
11. The method of claim 8 , wherein the acetone is evaporated overnight at room temperature.
12. The method of claim 8 , further comprising washing the polyvinyl benzoate nanoparticles, further comprising:
centrifuging the suspension of polyvinyl benzoate nanoparticles at 10,000 rpm for 10 minutes;
resuspending the pellet formed from the centrifugation in distilled water; and
sonicating the pellet for 1 minute to disperse any aggregates.
13. The method of claim 8 , further comprising:
freezing the polyvinyl benzoate nanoparticles at −70° C.; and
lyophilizing the polyvinyl benzoate nanoparticles for 24 hours.